B A C K G R O U N D Description of the condition
Endometrial cancer is the sixth most common cancer in women (GLOBOCAN 2012) . Worldwide there are more than 320,000 new cases of endometrial cancer each year, accounting for around 76,000 related deaths (GLOBOCAN 2012) . Compared to many other cancers, the prognosis for survival following endometrial cancer is good (Ferlay 2013). The 10-year survival rate in England and Wales is 77.6% (Cancer Research UK 2012). Early diagnosis explains this high survival rate, as most cases are diagnosed at an early stage and are effectively treated with surgery alone (Amanta 2015) . Women who are deemed to be at a higher risk of recurrence may receive postoperative adjuvant radiation therapy in the form of vaginal vault brachytherapy, or pelvic external-beam radiation therapy, with or without additional chemotherapy (NICE 2010) . In the UK, despite improvements in overall survival, there has been rise in incidence and mortality related to endometrial cancer (Evans 2011). Based on histopathology and clinical course, endometrial cancers can be divided into two categories: Type I and Type II (Hecht 2006) . Type I are typically low-grade (I to II) endometrioid adenocarcinomas, and are usually associated with unopposed oestrogen stimulation. These are usually diagnosed early and have a favourable prognosis. Type II endometrial cancers are commonly described as oestrogen-independent and are predominantly serous carcinomas (Emons 2000). They have poorer prognoses than Type I tumours, and account for 40% of endometrial cancer deaths, whereas they only account for 10% to 20% of cases (Moore 2011).
After completion of primary treatment, many women undergo long-term follow-up in secondary care (Kew 2006; Leeson 2013) . The aim of this follow-up is early detection of cancer recurrence or spread of disease, before the onset of symptoms. Recurrent disease may be more amenable to treatment at this stage, possibly leading to improved survival rates. These follow-up appointments also provide an opportunity for women to discuss any physical or psychological effects post treatment (Roberts 2009).
Description of the intervention
Follow-up care for endometrial cancer usually involves a review of current symptoms and a physical examination. Although not routine, especially for women with a low risk of recurrence, follow-up may include imaging procedures. Use of further investigations for the detection of recurrent endometrial cancer can be used (for example, chest radiology, serum tumour markers and vault cytology), but may detect asymptomatic recurrence without improving survival (Gordon 1997; Sartori 2010). In addition, many women with relapsed disease will not present at routine follow-up, but between scheduled appointments with abnormal symptoms. However, routine imaging procedures (magnetic resonance imaging (MRI)/computed tomography (CT)), vault cytology, serum tumour markers and other laboratory-based tests in the absence of symptoms are used to detect asymptomatic recurrence, whilst able to detect pre-clinical recurrence, have shown conflicting effects upon survival from retrospective data (Berchuck 1995; Carrara 2012; Owen 1996; Ueda 2010). Recent reports on the strategy for cancer in the UK and USA highlight the importance of designing a patient-centred approach, addressing the needs of service users, exploring women's and carers' perspectives and preferences for gynaecological cancer followup services in hospital, or potentially in a primary care setting, led by different professionals (Department of Health 2014; NCI 2010). However, the evidence base for the effectiveness of these approaches in detecting recurrent cancer or spread of disease is not robust (Kew 2005) . Studies have reported no survival benefit for women in detection of recurrent disease at an asymptomatic stage for endometrial cancer over and above current standard models of follow-up care. Many of these studies are non-randomised, retrospective and of poor methodological quality (Kew 2005). The evidence base for routine follow-up in other cancers can provide some guidance for the re-design of follow-up services for endometrial cancer. For example, in gynaecological cancers more generally, the detection of recurrence may be delayed because some women do not present with symptoms until their next routine appointment (Olaitan 2001). However, studies investigating recurrence for breast cancer reported most recurrences presenting between scheduled clinic appointments, which may cause a delay in detection of recurrence, pointing to the need for relatively frequent appointments (Olaitan 2001) . A meta-analysis of randomised controlled trials (RCTs) of follow-up after bowel cancer has suggested a benefit from intensive follow-up compared to little or no follow-up (Renehan 2002) although, larger trials are required to identify which components of intensive follow-up are most beneficial. Another meta-analysis of nine observational studies and one RCT reported survival benefits in intensive follow-up of women with lung cancer, although the authors noted that the observed benefit may be due to systematic differences in outcomes rather than intervention effects (Calman 2011). Intensive followup is thought to benefit the patient by either detecting recurrence early or offering reassurance and reducing anxiety about recurrence (Kew 2005; Kew 2009). There is little evidence to support this approach, particularly in terms of its effectiveness and costeffectiveness (Kew 2006). Given the financial pressures on health systems, there are limits to the extent to which provision of interventions for reassurance alone can be affordable.
How the intervention might work
A systematic review assessing the views of women and healthcare professionals about cancer follow-up has shown that fear of recurrence is the prime motivation for attending follow-up appointments (Lewis 2009a). It also highlighted that women found regular follow-up, expertise of specialists and quick access to tests reassuring. A recent study that examined the experiences of a gynaecological cancer diagnosis on women and their families, highlighted that living with the risk of cancer recurrence and spread of disease is a life-long social and psychological challenge, affecting the quality of life for women and their families, with women's approaches to managing that risk also affecting their plans for the future (Roberts 2009). One retrospective study suggested an improvement in survival when recurrent cervical cancer was detected at routine hospitalbased, doctor-led follow-up rather than waiting for symptoms to develop (Bodurka 2000). However, the majority of women relapsed with symptoms that would prompt reassessment, even if the patient did not have a scheduled routine follow-up appointment and had simply accessed primary care as a self-referral ( 
O B J E C T I V E S
To assess the clinical effectiveness and cost-effectiveness of different strategies in the follow-up of women with endometrial cancer after completion of primary treatment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs). Research looking at patients and their informal caregivers is being carried out as part of another study (Timmis 2015) and will form part of the 'Discussion' in the full review.
Types of participants
Women (18 and above) who have been diagnosed with endometrial (uterine) cancer. This will include type 1 (endometrioid) and type 2 tumours (Moore 2011), and any FIGO (FIGO 2015) stage according to the criteria in Appendix 1. All women must have completed primary treatment and be in the follow-up phase of care. We will exclude studies which focus on palliative treatment.
Types of interventions
We will consider any of the following comparisons.
Intensive follow-up
Protocol driven follow-up using various interventions including symptomatology, physical examination, serum tumour markers and radiological investigations. This could be either doctor-led or nurse-led in primary care or secondary care.
Non-intensive follow-up
• Follow-up of symptoms that are initiated by the patient and where further intervention and investigations are used as a response to the patient's initial report.
• Clinical needs driven follow-up using various interventions including symptomatology, physical examination, serum tumour markers and radiological investigations. This could be either doctor-led or nurse-led in primary care or secondary care.
The types of intervention will be categorised as follows: care setting, professional responsible, and components of follow-up.
Types of outcome measures Primary outcomes
• Overall survival (OS): survival until death from all causes (survival from the time when women were randomly assigned). Recurrence-free survival (RFS): defined by inclusion of recurrence or relapse of endometrial cancer (recurrence from the time when women were randomly assigned).
Secondary outcomes
• Quality of Life: We will report health-related Quality of Life (QoL) using validated QoL indices/scales, for example the cancer generic EORTC QLQ-C30 questionnaire (Fayers 2002a) in combination with FACT-En for endometrial cancer (McAlpine 2014).
• Cost-effectiveness: We will include studies that explore the relative cost-effectiveness of models of follow-up of women with endometrial cancer (economic evidence of follow-up after treatment for gynaecological cancer: cost-effectiveness, costutility, cost-consequences, cost-minimisation, cost-benefit or cost-analysis studies).
• Adverse events: applicable to endometrial cancer followup: increased anxiety, possibility of false-positive findings at follow-up resulting in further investigations.
Search methods for identification of studies Electronic searches
The following electronic databases will be searched for published literature using strategies that combine search terms relating to endometrial cancers and synonyms for follow-up:
• Cochrane Central Register of Controlled Trials (CENTRAL, the Cochrane Library, latest issue);
• MEDLINE (1946 to present date);
• Embase (1980 to present date); DARE (Database of Abstracts of Reviews of Effects);
• NHS EED (National Health Service Economic Evaluation Database) and;
• HTA (Health Technology Assessment) database.
All databases will be searched to the present date. We will use a search strategy developed and piloted in MEDLINE (see Appendix 2) and subsequently modified for use in the remaining databases. We are fairly confident that NHS EED is comprehensive for costeffectiveness studies to the end of December 2014 when its role changed. Hence, we will also run wider searches on MEDLINE and Embase for full economic evaluations from December 2014 to present date (Appendix 3)
Searching other resources Reference lists
We will conduct backward and forward citation tracking for all relevant studies and reviews in the field for further possible titles.
Unpublished and grey literature
Grey literature will be limited to practice guidelines published in the UK and will exclude posters, leaflets or abstracts unless these refer to relevant empirical studies. The relevant studies will then be sought and assessed according to our inclusion/exclusion criteria. We will search for ongoing trials in the following sources: Metaregister, Physicians Data Query, www.controlledtrials.com/, www.clinicaltrials.gov, www.cancer.gov/clinicaltrials, NHMRC Clinical Trials Register, UKCCCR, Register of Cancer Trials and Gynaecologic Oncologists of Canada.
Handsearching
Reports of conferences will be handsearched from the following sources.
• Meetings of the International Gynaecologic Cancer Society 
Data collection and analysis

Selection of studies
The database will be managed in EndNote X7. All titles and abstracts retrieved from the electronic searches will be downloaded to the reference management database and all duplicates will be removed. Two review authors will examine the remaining references in line with the inclusion/exclusion criteria, with one review author examining sections from each for quality control. Any studies that do not meet the inclusion criteria will be excluded. Remaining studies will be obtained as full-text articles and these will be independently assessed for eligibility by at least two review authors. A third review author will make the final decision on inclusion/exclusion should disagreement occur between the first and second review authors.
Data extraction and management
Two review authors will extract the following data using a pro forma, and a third review author will check a proportion of the studies for consistency.
• Characteristics of women (inclusion criteria, age, grade of cancer, co-morbidities, previous treatment, and whether there is residual disease at the start of follow-up).
• Number enrolled in each study arm, number enrolled at specific follow-up care time points, number lost to follow-up and how this was accounted for.
• Exact description of the follow-up protocols received by experimental and control groups (including whether clinician or patient initiated, care setting and frequency, use of investigations, timing of follow-up events; decision to give further treatment).
• Risk of bias, duration of follow-up, and outcomes and deviations from protocol.
• Recurrences which are patient-reported or cliniciandetected.
• Economic evidence of follow-up care after treatment for gynaecological cancer (cost-effectiveness, cost-utility, costconsequences, cost-minimisation, cost-benefit or cost analysis studies).
• For time to event (survival and recurrence) data, the log of the hazard ratio [log(HR)] and its standard error will be extracted from trial reports; if these are not reported, the log (HR) and its standard error will be estimated. (Parmar 1998).
• For dichotomous outcomes (e.g. adverse events or deaths, if it is not possible to use an HR), we will extract the number of women in each intervention arm who experienced the outcome of interest and the number of women assessed at end point, in order to estimate a risk ratio (RR).
• For continuous outcomes (e.g. QoL measures), the final value and standard deviation of the outcome of interest, and the number of women assessed at the endpoint in each intervention arm at the end of follow-up, will be extracted in order to estimate the mean difference (MD) between intervention arms and its standard error.
Both unadjusted and adjusted statistics will be extracted (Egger 2008), and where possible, all data extracted will be those relevant to an intention-to-treat analysis, whereby participants will be analysed in the groups to which they were assigned. Any disagreements will be resolved through discussion or by appeal to a third review author if necessary.
Assessment of risk of bias in included studies
We will assess the risk of bias in the included RCTs using Cochrane's 'Risk of bias' tool according to the following criteria as specified in Chapter 8 of the Cochrane Handbook for Systematic Reviews for Intervention (Higgins 2011, Appendix 4). Two review authors will independently apply the 'Risk of bias' tool and we will resolve disagreements by consensus or arbitration with a third author. We will summarise the results in both a 'Risk of bias' graph and a 'Risk of bias' summary. We will interpret the results of meta-analyses in the light of the findings with respect to risk of bias. Quality Appraisal for economic studies: We will use the Drummond checklist (Drummond 1996, Appendix 5) to assess the methodological quality of any economic studies included in the review.
Measures of treatment effect
We will use the following measures of the treatment effect.
• Hazard ratio (HR) for time-to-event data, if possible.
• Risk ratio (RR) for dichotomous outcomes.
• Mean difference (MD) between treatment arms and standard error for continuous outcomes.
Unit of analysis issues
We do not anticipate there will be any unit of analysis issues.
Dealing with missing data
Missing outcome data will not be imputed for any outcomes. Where we have missing or unclear data or information, we will contact the investigators of the primary research on the outcomes only for those participants who were assessed.
Assessment of heterogeneity
We will assess heterogeneity between studies by forest plots, by estimation of the percentage of heterogeneity between trials which cannot be ascribed to sampling variation (Deeks 2011), by a formal statistical test of the significance of the heterogeneity and, if possible, by subgroup analyses. If there is evidence of substantial heterogeneity, we will investigate this and report the reasons for it.
Assessment of reporting biases
Funnel plots corresponding to meta-analysis of the primary outcome will be examined to assess the potential for publication bias. If these plots suggest that treatment effects may not be sampled from a symmetrical distribution, we will perform further metaanalyses using a fixed-effect model.
Data synthesis
Clinically similar studies will be pooled in meta-analyses. If available, we will use adjusted summary statistics, otherwise we will use unadjusted results. For time-to-event data, we will pool HRs using the generic inverse variance facility in RevMan 5. For any dichotomous outcomes, we will calculate the RR for each study and pool the results. For continuous outcomes, if all trials measured the same outcome on the same scale, we will pool the MDs between the treatment groups at the end of follow-up; otherwise we will use the standardised mean difference (SMD) to pool results. If any trials have multiple treatment groups, the 'shared' comparison group will be divided into the number of treatment groups and comparisons between each treatment group and the split comparison group will be treated as independent comparisons. We will use a random-effects model with inverse variance weighting for all meta-analyses.
'Summary of findings' for assessing the quality of the evidence
Two review authors (RA and KP) will independently rate the quality of evidence for each outcome. We will provide a source and rationale for each assumed risk cited in the table(s) and we will use the GRADE system to rank the quality of the evidence using the GRADEprofiler Guideline Development Tool (GRADEproGDP) software (GRADEPro 2014) and the guidelines provided in Chapter 12.2 of the Cochrane Handbook for Systematic Reviews for Intervention (Schünemann 2011). We will present a summary of the evidence in a 'Summary of findings table' (Appendix 6), which provides key information about the best estimate of the magnitude of the effect, in relative terms and absolute differences for each relevant comparison of alternative management strategies, numbers of participants and studies addressing each important outcome and the rating of the overall confidence in effect estimates for the comparisons of each major primary outcomes, including potential harms, as outlined in the Types of outcome measures section. If meta-analysis is not possible, we will present results in a narrative 'Summary of findings' table format, such as that used by Chan 2011.
Subgroup analysis and investigation of heterogeneity
Where possible, subgroup analyses will be performed to explore:
• effect of disease status -residual versus no residual disease at commencement of follow-up;
• whether the intervention is modified by the caregiverdoctor versus nurse;
• effect of care setting: primary care versus secondary care; factors such as age, stage of disease, type of intervention, length of follow-up, adjusted/unadjusted analysis will be considered in interpretation of any heterogeneity.
Sensitivity analysis
We will perform sensitivity analyses in order to identify the effect of any assumptions on results, excluding studies at high risk of bias.
Ensuring relevance to decisions in health care
We will discuss the relevance to healthcare and delivery of services in the discussion section of the full review, This discussion will use guidance from national and international bodies as well information from qualitative studies which discuss the challenges facing women and the healthcare system.
A C K N O W L E D G E M E N T S
We are very grateful for the support of Valerie Morrison, Rhiannon Tudor Edwards, Rhiannon Whitaker, Marie Holmes, Richard Neal and Clare Wilkinson for assisting us in the protocol development.
We thank Jo Morrison for clinical and editorial advice, Clare Jess and Tracey Harrison for their contribution to the editorial process and Jane Hayes for designing the search strategy. This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group. The views and opinions expressed therein are those of the review authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.
